Table 4.
Acute effects of imeglimin 1 h after administration
| Group | Zucker fa/fa | |
|---|---|---|
| Untreated | Imeglimin | |
| Fasting plasma glucose (mmol/L) | 5.98 ± 0.46 | 5.15 ± 0.62 |
| Systolic blood pressure (mm Hg) | 145 ± 4 | 133 ± 4† |
| Diastolic blood pressure (mm Hg) | 105 ± 3 | 97 ± 3 |
| Heart rate (beats/min) | 371 ± 11 | 374 ± 9 |
| LV end‐systolic pressure (mm Hg) | 140 ± 4 | 123 ± 6† |
| LV end‐systolic pressure‐volume relation (mm Hg/RVU) | 25.2 ± 1.1 | 27.7 ± 1.9 |
| LV end‐diastolic pressure (mm Hg) | 3.57 ± 0.35 | 2.80 ± 0.43 |
| LV relaxation constant Tau (msec) | 7.89 ± 0.18 | 7.03 ± 0.24† |
| LV end‐diastolic pressure‐volume relation (mmHg/RVU) | 3.38 ± 0.18 | 1.90 ± 0.07† |
| LV myocardial tissue perfusion (ml/min/g) | 4.51 ± 0.26 | 6.24 ± 0.52† |
| LV ROS production (AU/µg/h) | 20.64 ± 0.77 | 18.21 ± 0.83 (P = .06) |
| Plasma Nitrite levels (nmol/L) | 297 ± 26 | 648 ± 92† |
| LV mitochondrial ROS (AU/µg/h) | ||
| Subsarcolemma | 6407 ± 779 | 4319 ± 485† |
| Interfibrillar | 2953 ± 413 | 2116 ± 532 |
†
P < .05 vs untreated Zucker fa/fa.